Rapid quantification of valsartan in human plasma by liquid chromatography using a monolithic column and a fluorescence detection: Application for pharmacokinetic studies

Scientia Pharmaceutica

Volumn 76, Issue 3, 2008, Pages 439-450

  Zarghi, Afshin ^a   Shafaati, Alireza ^a   Foroutan, Seyed Mohsen ^a   Movahed, Hooman ^b  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b Noor Research and Educational Institute   (Iran)

Author keywords

HPLC; Monolithic column; Pharmacokinetic study; Plasma; Valsartan

Indexed keywords

VALSARTAN;

ACCURACY; AREA UNDER THE CURVE; ARTICLE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG STABILITY; FLUORESCENCE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; QUANTITATIVE ANALYSIS; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION;

EID: 52449117747     PISSN: 00368709     EISSN: 22180532     Source Type: Journal    
DOI: 10.3797/scipharm.0808-01     Document Type: Article

References (13)

1. Croom K F, Keating G M. Valsartan: a review of its use in patients with heart failure and/or left ventricular systolic dysfunction after myocardial infarction. Am J Cardiovasc Drugs. 2004; 4: 395-404. [doi:10.2165/00129784- 200404060-00008]
2. Waldmeier F, Flesch G, Müller P, Winkler T, Kriemler H P, Bühlmayer P, De Gasparo M. Pharmacokinetics, disposition and biotransformation of [14C]-radiolabelled valsartan in healthy male volunteers after a single oral dose. Xenobiotica. 1997; 27: 59-71. [doi:10.1080/ 004982597240767]
3. Flesch G, Muller P, Lloyd P. Absolute bioavailability and pharmacokinetics of valsartan, an angiotensin II receptor antagonist, in man. Eur J Clin Pharmacol. 1997; 52: 115-120. [doi:10.1007/S002280050259]
4. Daneshtalab N, Lewanczuk R. Z, Jamali F. High-performance liquid chromatographic analysis of angiotensin II receptor antagonist valsartan using a liquid extraction method. J Chromatogr B. 2002; 766: 345-349. [doi:10.1016/S0378-4347(01)00507-2]
5. Schmidt E K, Antonin K H, Flesch G, Racine-Poon A. An interaction study with cimetidine and the new angiotensin II antagonist valsartan. Eur J Clin Pharmacol. 1998; 53: 451-458. [doi:10.1007/S002280050406]
6. Sioufi A, Marfil F, Godbillon J. Automated determination of an angiotensin II receptor antagonist CGP 48 933, in plasma by high-performance liquid chromatography. J Liq Chromatogr. 1994; 17: 2179-2186. [doi:10.1080/10826079408013539]
7. Gonzalez L, Lopez J A, Alonso R M, Jimenez R M. Fast screening method for the determination of angiotensin II receptor antagonists in human plasma by high-performance liquid chromatography with fluorimetric detection. J Chromatogr A. 2002; 949: 49-60. [doi:10.1016/S0021-9673(01)01496-0]
8. Brunner L A, Powell M L, Degen P. A semiautomated analytical method for the determination of potentialantihypertensive agents (CGP 48933 and/or CGP 48369) in human plasma using high-performance liquid chromatography. Lab Robot Automat. 1994; 6: 171-179.
9. Sechaud R, Graf P, Bigler H, Gruendi E, Letzkus M, Merz M. Bioequivalence study of a valsartan tablet and a capsule formulation after single dosing in healthy volunteers using a replicated crossover design. Int J Clin Pharmacol Ther. 2002; 40: 35-40.
10. Macek J, Klima J, Ptacek P. Rapid determination of valsartan in human plasma by protein precipitation and high-performance liquid chromatography. J Chromatogr B. 2006; 832: 169-172. [doi:10.1016/j.jchromb.2005.12.035]
11. Koseki N, Kawashita H, Hara H, Niina M, Tanaka M, Kawai R, Nagae Y, Masuda N. Development and validation of a method for quantitative determination of valsartan in human plasma by liquid chromatography-tandem mass spectrometry. J Pharm Biomed Anal. 2007; 43: 1769-1774. [doi:10.1016/j.jpba.2006.12.030]
12. Cabrera K. Applications of silica-based monolithic HPLC columns. J Sep Sci. 2004; 27: 843-852. [doi:10.1002/jssc.200401827]
13. Miyabe K, Guiochon G. Characterization of monolithic columns for HPLC. J Sep Sci. 2004; 27:853-873. [doi:10.1002/jssc.200401772]